Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
Portfolio Pulse from Benzinga Insights
Ionis Pharmaceuticals (NASDAQ:IONS) has received mixed evaluations from 6 analysts over the past three months, with a combination of bullish and somewhat bullish ratings. The average 12-month price target is $65.0, with a high of $82.00 and a low of $53.00. Recent analyst actions include rating adjustments and price target changes, reflecting evolving market conditions and company performance. Ionis faces challenges in revenue growth, net margin, ROE, ROA, and debt management.
June 27, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ionis Pharmaceuticals has received mixed ratings from analysts, with an average 12-month price target of $65.0. The company faces challenges in revenue growth, net margin, ROE, ROA, and debt management.
The mixed analyst ratings and the average price target of $65.0 suggest a neutral short-term impact on the stock price. The company's financial challenges in revenue growth, net margin, ROE, ROA, and debt management further support a neutral outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100